In clinical research, 99mTc-HYNIC-annexin V imaging using a recombinant human form of annexin V has been used to assess myocardial infarction, heart transplant rejection, atherosclerosis, ischemic pre-conditioning and chemotherapy/radiation therapy-induced apoptosis in head and neck cancers, lymphomas, lung cancers, breast cancers, leukaemia and soft tissue sarcomas. The gene discussed is ANXA5; the disease is breast carcinoma.